معرفی
Mitchell McInerney is a Research Fellow in the Department of Biochemistry and Molecular Biology at Monash University, affiliated with the Monash Biomedicine Discovery Institute (Monash BDI). His research leverages advanced mass spectrometry techniques to investigate immunological processes and disease mechanisms, particularly in the context of drug discovery and metabolite identification.
His research interests span mass spectrometry, immunology, pharmacology, and neuropharmacology, with a focus on understanding how biometals and ionophores influence P-glycoprotein expression at the blood-brain barrier. His expertise includes liquid chromatography, acoustic ejection, triple quadrupole, QTOF, and Orbitrap mass spectrometry, which he applies to diverse biological questions.
The recent publications highlight a strong trend in both pharmaceutical formulation science and immunometabolism. His work bridges computational modeling, experimental pharmacology, and clinical translation, particularly in drug delivery systems and immune recognition of metabolites. The 2024 paper on MR1 and vitamin B6-related compounds marks a significant contribution to understanding T cell activation mechanisms.
No scientific awards are currently listed in the provided text.
Mitchell McInerney has collaborated extensively with researchers at Monash University, particularly within the pharmaceutical sciences and immunology domains. His work has been supported by institutional research infrastructure, though specific grants are not mentioned. He has co-authored multiple peer-reviewed articles, primarily in high-impact pharmaceutical and biochemical journals.
He is involved in research teams focused on drug metabolism, blood-brain barrier transport, and immunological recognition, primarily operating within the collaborative environment of Monash BDI and MIPS.
